Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

doi:10.1158/1078-0432.CCR-16-1863

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2017

Pietrantonio Filippo, Vernieri Claudio, Siravegna Giulia, Mennitto Alessia, Berenato Rosa, Perrone Federica, Gloghini Annunziata, Tamborini Elena, Lonardi Sara, Morano Federica, Picciani Benedetta, Busico Adele, Volpi Chiara Costanza, Martinetti Antonia, Battaglin Francesca, Bossi Ilaria, Pellegrinelli Alessio, Milione Massimo, Cremolini Chiara, Di Bartolomeo Maria, Bardelli Alberto, de Braud Filippo

Abstract excerpt

Purpose: Even if RAS-BRAF wild-type and HER2/MET-negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired resistance almost invariably occurs. Mechanisms of resistance to EGFR blockade include the emergence of KRAS, NRAS, and EGFR extracellular domain mutations as well as HER2/MET alterations. However, these findings derive from retrospective studies that analyzed one...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Disease-Free Survival

Share to GTP Phosphohydrolases

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Source

Open in PubMed

Identifiers

PMID: 27780856
DOI: 10.1158/1078-0432.CCR-16-1863

Genes

EGFR
MET
BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.PMID 27780856Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy.Semantic proximity Read ↗

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.Semantic proximity Read ↗

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Semantic proximity Read ↗

Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.Semantic proximity Read ↗

Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer.Semantic proximity Read ↗

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal CancerSemantic proximity Read ↗

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read ↗

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read ↗

Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNASemantic proximity Read ↗

Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.